PUBLICATION OF ADDITIONAL PROSPECTUS FROM SCN

(NGM:SCN)

Scandinavian Clinical Nutrition i Sverige AB (publ) herewith publishes an additional prospectus, approved and registered by the Swedish Financial Supervisory Authority, which constitutes an addition to the prospectus which was published, registered and approved by the Swedish Financial Supervisory Authority on May 20, 2008.

On May 20, 2008, SCN published a prospectus regarding issue of maximum 1,232,560 shares and 1,232,560 convertible bonds with preferential right for the company’s shareholders (“the Prospectus”). The Prospectus was approved and registered by the Swedish Financial Supervisory Authority on the same day.

Since the Annual General Meeting in SCN, which was held on May 22, 2008, decided to elect a new Board for the company, SCN today (June 2, 2008) publishes an addition to the Prospectus (the “Additional Prospectus”). The Prospectus is to be read together with this Additional Prospectus, which is available as an attachment to this press release as well as on the company’s website www.scnutrition.com.

This Additional Prospectus has been approved and registered by the Swedish Financial Supervisory Authority in accordance with the regulations in the 2nd chapter, 34 § of the Financial Instrument Trading Act (1990:980). Should there be any discrepancies between this Additional Prospectus and the Prospectus, or other documents included in the Prospectus by reference, this Additional Prospectus has precedence.

Investors who have subscribed for shares and convertible bonds in the issue and wish to recall their subscription notice or consent due to the publication of this Additional Prospectus must do so within five working days from the publication of this Additional Prospectus.

For more information, please contact:

Thomas Christensen, CEO, tc@scnutrition.com, +47 922 55 444

Ulf Söderberg, Chairman of the Board, us@scnutrition.com, +46 708 13 22 81

Scandinavian Clinical Nutrition AB (publ) works in R&D and sales of scientifically documented products within the field of nutrition (nutraceuticals). Established in 2006, SCN maintains a product portfolio with established trademarks, such as CUUR, Coldizin, Immulina and Ledactin. Core competence and strategic alliances within both R&D and sales, in combination with innovative and scientifically documented products, create the right conditions for profitable growth on the international market. The shares of SCN are traded under the ticker “SCN” on Oslo Axess (www.osloaxess.no) and NGM Equity (www.ngm.se).

(For Prospectus see attached file.)